2021
DOI: 10.1007/s12254-021-00775-5
|View full text |Cite
|
Sign up to set email alerts
|

The outcome of COVID-19 in patients with hematological malignancy

Abstract: Objective The aim of this study was to examine the effect of coronavirus disease 2019 (COVID-19) on the malignancy-related clinical course and overall survival, and to determine the factors affecting mortality. Methods This retrospective study included 77 patients with hematological cancer and COVID-19. Patients were sub-grouped for analysis as survivors and non-survivors. Results COVID-19 was seen more frequently in myeloproliferative neopla… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 9 publications
(17 citation statements)
references
References 28 publications
1
15
0
1
Order By: Relevance
“…The demographic and clinical characteristics of the patients are given in Table 1. Since the malign disease group in this study was used in a published study, the mentioned study was cited for the demographic and disease-related characteristics of the malign hematologic disease group in this study (Tığlıoğlu et al, 2022). AIHA: autoimmune hemolytic anemia, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CAD: coronary artery disease, CDA: congenital dyserythropoietic anemia, CKD: chronic kidney disease, CLL: chronic lymphocytic leukemia, CML: chronic myeloid leukemia, COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate, HL: Hodgkin lymphoma, MDS: myelodysplastic syndrome, MM: multiple myeloma, MPN: Myeloproliferative neoplasms, NHL: non-Hodgkin lymphoma, Ph: Philadelphia chromosome, TTP:Thrombotic thrombocytopenic purpura Eighty eight patients who had COVID-19 infection while being followed in our clinic due to hematological diseases were included in the study.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…The demographic and clinical characteristics of the patients are given in Table 1. Since the malign disease group in this study was used in a published study, the mentioned study was cited for the demographic and disease-related characteristics of the malign hematologic disease group in this study (Tığlıoğlu et al, 2022). AIHA: autoimmune hemolytic anemia, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CAD: coronary artery disease, CDA: congenital dyserythropoietic anemia, CKD: chronic kidney disease, CLL: chronic lymphocytic leukemia, CML: chronic myeloid leukemia, COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate, HL: Hodgkin lymphoma, MDS: myelodysplastic syndrome, MM: multiple myeloma, MPN: Myeloproliferative neoplasms, NHL: non-Hodgkin lymphoma, Ph: Philadelphia chromosome, TTP:Thrombotic thrombocytopenic purpura Eighty eight patients who had COVID-19 infection while being followed in our clinic due to hematological diseases were included in the study.…”
Section: Resultsmentioning
confidence: 99%
“…fourty six (60%) of the patients had at least one comorbidity. The most common comorbidities were HT, diabetes and COPD, respectively (Tığlıoğlu et al, 2022) . Immune thrombocytopenia (ITP) (64%) was the most common disease in patients with benign hematological disorder who had COVID history.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…13 In light of these data, we may think that COVID-19 leads to higher mortality rates in patients with hematological malignancies. 2,5,7,14 The possible association between the type of hematological cancer and mortality is another speculated issue. According to the European Survey, the highest mortality rates were detected in patients with acute myeloid leukemia and myelodysplastic syndromes.…”
Section: Methodsmentioning
confidence: 99%
“…1,[3][4][5] Hematological disorders such as myeloproliferative disorders, leukemia, lymphomas, and myelodysplastic syndromes are among the most vulnerable cohorts for COVID-19, considering the worse outcomes. 2,4,[6][7][8] The development of severe infections leads to worsening clinical outcomes in these patients. 2,9,10 Hematological malignancies have been responsible for more severe clinical conditions due to COVID-19 infection than solid organ tumors.…”
Section: Introductionmentioning
confidence: 99%